News of the WeekClinical Research

Hopkins Reviews Investment in Indian Cancer Drug Trial

Science  10 Aug 2001:
Vol. 293, Issue 5532, pp. 1024
DOI: 10.1126/science.293.5532.1024

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution

This article has a correction. Please see:


Now add financial interest to the mix of combustible elements in the controversy over tests of a new drug for oral cancer in India. Johns Hopkins University, whose professor helped design a trial at the Regional Cancer Center of Trivandrum, India, has also invested in a Minnesota start-up medical company that plans to test the drug at other Asian sites. Hopkins is also trying to explain how it could have sent a check to support the cancer study in India without first seeking approval from a university ethics panel. (See Editorial in this issue.)